Sugi Predict

Sugi Predict / Compounds / SCHEMBL3671285

SCHEMBL3671285

SCHEMBL3671285

NC(=O)C1(c2ccccn2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 3/20 0.50
▸ OPRM1 P35372 2/20 0.49
▸ OPRL1 P41146 2/20 0.49
▸ RIPK1 Q13546 1/20 0.42
▸ GRIN1 Q05586 1/20 0.40
▸ GRIN2A Q12879 1/20 0.40
▸ GRIN2B Q13224 1/20 0.40
▸ SLC6A2 P23975 1/20 0.40
▸ SLC6A4 P31645 1/20 0.40
▸ CES2 O00748 1/20 0.39
▸ CES1 P23141 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ OPRD1 P41143 1/20 0.39
▸ OPRK1 P41145 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ LMNA P02545 1/20 0.38
▸ NAPRT Q6XQN6 1/20 0.38
▸ P4HTM Q9NXG6 1/20 0.38
▸ CHRM2 P08172 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29388865 1.00 HSD11B1 (0.50) HSD11B1OPRM1OPRL1RIPK1GRIN1
Hydrochloric Acid SCHEMBL21047312 0.98 HSD11B1 (0.49) HSD11B1OPRM1OPRL1RIPK1GRIN1
Formic Acid SCHEMBL3655345 0.93 HSD11B1 (0.46) HSD11B1OPRM1OPRL1RIPK1GRIN1
Phosphoric Acid SCHEMBL30852681 0.93 HSD11B1 (0.46) HSD11B1OPRM1OPRL1RIPK1GRIN1
SCHEMBL1515554 0.93 HSD11B1 (0.48) HSD11B1OPRM1OPRL1RIPK1GRIN1
SCHEMBL8547420 0.91 HSD11B1 (0.53) HSD11B1OPRM1OPRL1RIPK1GRIN1
SCHEMBL30852569 0.91 HSD11B1 (0.44) HSD11B1OPRM1OPRL1RIPK1SLC6A2
SCHEMBL25193081 0.90 OPRM1 (0.45) HSD11B1OPRM1OPRL1RIPK1GRIN1
Hydrochloric Acid SCHEMBL29842435 0.90 HSD11B1 (0.52) HSD11B1OPRM1OPRL1RIPK1GRIN1
SCHEMBL8636435 0.89 OPRM1 (0.44) HSD11B1OPRM1OPRL1RIPK1GRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109563085-B Piperidine CXCR7 receptor modulators 爱杜西亚药品有限公司 2022-08-09 — — CN claimed
EP-3490986-B1 PIPERIDINE CXCR7 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2021-11-24 — — EP claimed
US-10752620-B2 Piperdine CXCR7 receptor modulators IDORSIA PHARMACEUTICALS LTD. (CH) 2020-08-25 — — US claimed
US-20190169180-A1 PIPERDINE CXCR7 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2019-06-06 — — US claimed
EP-3490986-A1 PIPERIDINE CXCR7 RECEPTOR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2019-06-05 — — EP claimed
WO-2018019929-A1 PIPERIDINE CXCR7 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2018-02-01 — — WO claimed
US-11746091-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2023-09-05 — — US disclosed
EP-3798217-B1 PIPERIDINE CXCR7 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2023-02-22 — — EP disclosed
US-20230033510-A1 Compounds and Methods for Treatment of Visceral Pain ARENA PHARMACEUTICALS, INC. 2023-02-02 — — US disclosed
CN-110563717-B Piperidine CXCR7 receptor modulators 爱杜西亚药品有限公司 2022-08-09 — — CN disclosed
CN-109563085-B Piperidine CXCR7 receptor modulators 爱杜西亚药品有限公司 2022-08-09 — — CN disclosed
US-11306078-B2 Piperidine CXCR7 receptor modulators IDORSIA PHARMACEUTICALS LTD. (CH) 2022-04-19 — — US disclosed
US-11214548-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2022-01-04 — — US disclosed
WO-2009136663-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-12 — — WO disclosed
US-7595405-B2 Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists ROCHE PALO ALTO LLC (US) 2009-09-29 — — US disclosed
WO-2008150015-A1 HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-11 — — WO disclosed
US-20080004442-A1 Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists ROCHE PALO ALTO LLC 2008-01-03 — — US disclosed
WO-2006071035-A1 NOVEL ([1,3]THIAZOLO[5,4-B]PYRIDIN-2-YL)-2-CARBOXAMIDE DERIVATIVES LG LIFE SCIENCES, LTD. (KR) 2006-07-06 — — WO disclosed
EP-0243971-B1 Fungicidal pyridyl cyclopropane carboxamides STAUFFER CHEMICAL CO (US) 1994-08-03 — — EP disclosed
EP-0243971-A2 Fungicidal pyridyl cyclopropane carboxamides STAUFFER CHEMICAL COMPANY (US) 1987-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11306078-B2 Piperidine CXCR7 receptor modulators CXCR1, CXCR5, ACKR3 HSD11B1 1995/4885OPRM1 112/4885OPRL1 59/4885
US-20190169180-A1 PIPERDINE CXCR7 RECEPTOR MODULATORS CXCR1, CXCR5, ACKR3 HSD11B1 1798/4885OPRM1 93/4885OPRL1 50/4885
US-11746091-B2 Cannabinoid receptor modulators CNR1, CNR2, TRPV1 HSD11B1 3497/4885OPRM1 15/4885OPRL1 4/4885
US-11214548-B2 Cannabinoid receptor modulators CNR1, CNR2, TRPV1 HSD11B1 3497/4885OPRM1 15/4885OPRL1 4/4885
US-20080004442-A1 Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists P2RX3, P2RX2, P2RX5 HSD11B1 3763/4885OPRM1 1057/4885OPRL1 293/4885
US-20230033510-A1 Compounds and Methods for Treatment of Visceral Pain VIP, FABP2, FABP6 HSD11B1 716/4885OPRM1 50/4885OPRL1 12/4885
US-10752620-B2 Piperdine CXCR7 receptor modulators CXCR1, CXCR5, ACKR3 HSD11B1 1798/4885OPRM1 93/4885OPRL1 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.